Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
IPO Year:
Exchange: NASDAQ
Website: nektar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/11/2025 | $2.00 | Hold → Buy | Jefferies |
| 3/14/2025 | $6.00 | Perform → Outperform | Oppenheimer |
| 1/8/2025 | $4.00 | Buy | B. Riley Securities |
| 12/10/2024 | $6.50 | Buy | H.C. Wainwright |
| 11/4/2024 | $7.00 | Overweight | Piper Sandler |
| 9/30/2024 | $4.00 | Buy | BTIG Research |
| 6/28/2024 | $2.00 | Buy | Rodman & Renshaw |
| 11/20/2023 | Underweight | JP Morgan | |
| 11/9/2023 | Market Perform → Outperform | TD Cowen | |
| 5/10/2023 | $1.50 → $1.00 | Underperform → Hold | Jefferies |
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)
SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)
SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a
SAN FRANCISCO, May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 20
SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar w
SAN FRANCISCO, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m. PST. Nektar's Chief Research & Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes experts, including: Dr. Kevin Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine;Dr. Megan Levings, Professor, D
SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We made excellent progress this quarter advancing our I&I pipeline, including the ongoing Phase 2b studies of rezpegaldesleukin in atopic
SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/
SAN FRANCISCO, Aug. 8, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the second quarter ended June 30, 2024. Cash and investments in marketable securities at June 30, 2024 were $290.6 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026. "We continue to make excellent progress advancing rezpegaldesleukin in Phase 2 studies in patients with atopic dermatitis and alopecia areata," said
SAN FRANCISCO, Aug. 1, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the second quarter 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/.
SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2024. Cash and investments in marketable securities at March 31, 2024 were $326.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the third quarter of 2026. "In the first quarter, we made significant progress with our highly promising immunology and inflammation pipeline," said Howard W. Robin, President
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
5 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)
Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh
BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and
SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple
SAN FRANCISCO, July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer (CMO). In his role as CMO, Dr. Nuyten will have oversight for the company's clinical strategy and activities, including direct supervision of clinical sciences, clinical operations, data science and systems, medical affairs and clinical pharmacology. Dr. Nuyten will also serve as a member of the Company's Executive Committee. Dr. Nuyten has extensive experience establishing an
SAN FRANCISCO, Jan. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately. Since 2017, Dr. Kotzin has served as Senior Vice President, Clinical Development and Head of Immunology at Nektar. Wei Lin will be leaving the company to pursue another opportunity. (PRNewsfoto/Nektar Therapeutics) "We are pleased that Dr. Kotzin will take on this key role on our development team at Nektar," said Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics. "Since he joined Nektar in 2017, Dr. Kotzin has demonstrated strong leadership and strate
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
DEF 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)
PRE 14A - NEKTAR THERAPEUTICS (0000906709) (Filer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
EFFECT - NEKTAR THERAPEUTICS (0000906709) (Filer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
S-3 - NEKTAR THERAPEUTICS (0000906709) (Filer)
S-8 - NEKTAR THERAPEUTICS (0000906709) (Filer)
10-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)
SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a
SAN FRANCISCO, May 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter on Thursday, May 8, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. The web
SAN FRANCISCO, March 20, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time – webcast link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-pres
SAN FRANCISCO, March 12, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash and investments in marketable securities on December 31, 2024 were $269.1 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 20
SAN FRANCISCO, March 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar w
SAN FRANCISCO, Feb. 26, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs). Results from multiple clinical trials showed that rezpegaldesleukin safely and dose-dependently increased Tregs.1 "We
SAN FRANCISCO, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m. PST. Nektar's Chief Research & Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetes experts, including: Dr. Kevin Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine;Dr. Megan Levings, Professor, D
-- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D). Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immu
SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells (Tregs).
SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical activity in multiple skin disease settings. Results from multiple clinical trials showed that rezpegaldesleukin safely and dose-dependently increased Tregs and
Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00
Oppenheimer upgraded Nektar Therapeutics from Perform to Outperform and set a new price target of $6.00
B. Riley Securities initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00
H.C. Wainwright initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $6.50
Piper Sandler initiated coverage of Nektar Therapeutics with a rating of Overweight and set a new price target of $7.00
BTIG Research resumed coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $4.00
Rodman & Renshaw initiated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $2.00
JP Morgan resumed coverage of Nektar Therapeutics with a rating of Underweight
TD Cowen upgraded Nektar Therapeutics from Market Perform to Outperform
Jefferies upgraded Nektar Therapeutics from Underperform to Hold and set a new price target of $1.00 from $1.50 previously